GT Biopharma (GTBP) EBITDA Margin (2010 - 2015)

GT Biopharma (GTBP) has reported EBITDA Margin for 5 consecutive years, with 7155.0% the latest figure, recorded in Q2 2015.

• On a quarterly basis, EBITDA Margin changed N/A year-over-year to 7155.0% in Q2 2015; TTM through Mar 2016 was 55085.0%, a 5377736.0% decrease from a year earlier, with the FY2015 full-year figure at 33062.96%, down 2913509.0% from the prior year.
• EBITDA Margin was 7155.0% for Q2 2015 at GT Biopharma, up from 25871.43% in the prior quarter.
• Over five years, EBITDA Margin peaked at 337.44% in Q4 2012 and troughed at 103000.0% in Q2 2012.
• A 4-year average of 26986.96% and a median of 25871.43% in 2015 frame the typical range for EBITDA Margin.
• Across the five-year window, EBITDA Margin plunged 5490000 bps in 2012 and soared 3920568 bps in 2013, its largest moves.
• Over 4 years, EBITDA Margin stood at 34933.33% in 2011, then surged by 99 bps to 337.44% in 2012, then decreased by 17 bps to 394.32% in 2013, then sank by 1715 bps to 7155.0% in 2015.
• The last three EBITDA Margin figures came in at 7155.0% (Q2 2015), 25871.43% (Q1 2015), and 394.32% (Q1 2013), per Business Quant data.